LBA Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

LBA Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$2K	Hold	13	–	–	﹤0.01%	424
2016 Q4	$2K	Hold	13	–	–	﹤0.01%	425
2016 Q3	$2K	Hold	13	–	–	﹤0.01%	418
2016 Q2	$2K	Hold	13	–	–	﹤0.01%	404
2016 Q1	$2K	Hold	13	–	–	﹤0.01%	396
2015 Q4	$2K	Hold	13	–	–	﹤0.01%	387
2015 Q3	$2K	Hold	13	–	–	﹤0.01%	320
2015 Q2	$2K	Buy	+13	New	+$2.24K	﹤0.01%	304

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

LBA Wealth Management's ALXN Position: Q1 2017 in Review

LBA Wealth Management held its Alexion Pharmaceuticals (ALXN) position steady in Q1 2017 at 13 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

LBA Wealth Management first reported a position in ALXN in Q2 2015 and has held it in 8 quarters since. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

LBA Wealth Management held 13 shares of Alexion Pharmaceuticals worth $2K as of Q1 2017.
LBA Wealth Management left its Alexion Pharmaceuticals share count unchanged in Q1 2017.
Alexion Pharmaceuticals made up ﹤0.01% of LBA Wealth Management's portfolio in Q1 2017, its #424 holding.
LBA Wealth Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and has held it in 8 quarters since.
561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on LBA Wealth Management's 13F filing for Q1 2017, filed 9 May 2017.